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H.inﬂuenzae decreasing in the pathogens list. If pneumococcal
conjugate vaccine-13 incorporated into Universal Immunization
Programme, it can provide protection against 79% of serotypes
responsible for Invasive pneumococcal diseases in India. However
continued surveillance representing all parts of the country is nec-
essary to understand the complete picture of Invasive bacterial
diseases in India
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Evaluation of passive pharmacovigilance
surveillance system in Tanzania – a review of
secondary data
J.V. Kapinga
Mkinga District Council, Tanga, Tanzania, United
Republic of
Background: Tanzania Food and Drugs Authority (TFDA) rou-
tinely collects adverse drug reactions (ADRs) data to detect, prevent
ADRs, protect public health, and reduce avoidable costs to the
health care system through passive pharmacovigilance surveil-
lance. Under – reporting is a challenge and limited epidemiological
evaluations of the system have been conducted. This study evalu-
ated the systemtodetermineperformanceof the system inmeeting
its objectives and its attributes and provide recommendations
Methods & Materials: CDC guidance (MMWR 2001) for eval-
uation of public health surveillance system was used. Review of
secondary data for the period 2006 – 2013, and key informant
interviews were conducted.
Results: Between2006and2013,630ADRscaseswere reported,
108 (1.4%) cases reported in 2013 compared to 8000 expected
cases annually. All interviewed health care providers (HCPs), know
ADRs case deﬁnitions, three trained on ADRs surveillance, two
send reports to TFDA. Among 36 sampled reported forms, 27 (75%)
were incompletely ﬁlled, 7(19.4%) correctly ﬁlled, 9(25%) received
at TFDA timely. From January –December 2013, 108 cases were
located in the data base while 80 cases found in reported forms.
Among seven visited health facilities, ﬁve had only yellow forms
and two reported ADRs cases to TFDA. Data management and anal-
ysis is done at TFDA headquarters.
Conclusion: The systemmet some of its objectives: it is ﬂexible,
stable and representative but not simple, acceptable, and has poor
data quality and timeliness. HCPs and public awareness on ADRs
reporting should be increased. The system should be integrated
into government health administrative levels, including followups.
Supportive supervision and data transmission mechanisms should
be improved.
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Device-associated infection rates with
microbiological proﬁle and antibiogram pattern
from an adult medical-surgical ICU of a tertiary
care hospital
B. Kashyap ∗, S. Gupta, Y. Sarin
Maulana Azad Medical College, New Delhi, India
Background: Intensive care unit (ICU) is considered the epi-
center for health care associated infections (HAIs) due to the
underlying disease severity with comorbidities, increased use of
invasive interventions and wide spectrum antibiotics. Ubiquitous
medical devices, continuing to be essential in permitting lifesaving
treatment among critically ill patients, unfortunately are a major
cause of HAIs especially in the ICUs.
Methods & Materials: A prospective surveillance was imple-
mented in a 15 bedded adultmedical surgical ICU of a 2500 bedded
tertiary care hospital from March to August 2015. Central line-
associated bloodstream infection (CLABSI), ventilator-associated
pneumonia (VAP) and catheter-associated urinary tract infec-
tion (CAUTI) were deﬁned and the DA-HAI rates were calculated
using the Centers of Disease Control National Nosocomial Infec-
tions Surveillance System and National Healthcare Safety Network
guidelines.
Results: During the study period 564 patients were admit-
ted for 2192 days. Fifty four episodes of DAI were documented,
55.55% belonging to age group 31-60 years with male to female
ratio of 1.57. Average length of stay was 8-14 days in 37% of the
54 DA-HAI cases among whom 68.52% had a fatal outcome. DA-
HAI rates for VAP, CLABSI and CAUTI were 16.74, 10.33 and 7.31
respectively with the overall DANI (device associated nosocomial
infection) rate of 24.64 DAI per 1000 ICU days. The device utiliza-
tion ratio was maximum for urinary catheter (0.99) followed by
0.68 for ventilator and 0.57 for central line. The overall ALOS (aver-
age length of survival) was 6.62 days whereas the crude overall
case-fatality was 68.52% for patients who acquired a DA-HAI and
38.24% for thosewithout a DA-HAI, yielding an overall crude excess
mortality of 30.28%. Overall 40.74% of DA-HAIs were caused by
Klebsiella species followednext byAcinetobacter species in 25.93%.
Cephalosporins were the most resistant (80-100%) against gram
negative organisms while imipenem (79.16%) and vancomycin
(75%) showed maximum sensitivity to gram negative and posi-
tive organisms respectively. No colistin or linezolid resistant gram
negative or gram positive isolated was reported.
Conclusion: Surveillance of DA (device associated) HAIs allows
a valid estimation of the effectiveness of quality improvement
activities or any new infection control measure adopted.
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